MABCAMPATH

This brand name is authorized in Canada, Japan, Turkey.

Active ingredients

The drug MABCAMPATH contains one active pharmaceutical ingredient (API):

1	Alemtuzumab UNII 3A189DH42V - ALEMTUZUMAB
	Alemtuzumab is a genetically engineered humanised IgG1 kappa monoclonal antibody specific for a 21-28 kD lymphocyte cell surface glycoprotein (CD52) expressed primarily on the surface of normal and malignant peripheral blood B and T cell lymphocytes. Alemtuzumab acts through antibody-dependent cellular cytolysis and complement-mediated lysis following cell surface binding to CD52, a cell surface antigen present at high levels on T (CD3+) and B (CD19+) lymphocytes, and at lower levels on natural killer cells, monocytes, and macrophages.
	Read more about Alemtuzumab

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
MabCampath 30mg/ml concentrate for solution for infusion	MPI, EU: SmPC	Medicines & Healthcare Products Regulatory Agency (GB)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
L04AG06	Alemtuzumab	L Antineoplastic and immunomodulating agents → L04 Immunosuppressants → L04A Immunosuppressants → L04AG Monoclonal antibodies
Discover more medicines within L04AG06

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
CA	Health Products and Food Branch	02290960
JP	医薬品医療機器総合機構	4291428A1029
TR	İlaç ve Tıbbi Cihaz Kurumu	8699545766643